Literature DB >> 31782721

Clinical impact of repeat renal biopsies in patients with lupus nephritis: Renal biopsy is essential especially later in the course of the disease.

Smaragdi Marinaki1, Eleni Kapsia1, George Liapis2, Hariklia Gakiopoulou2, Chrysanthi Skalioti1, Kyriaki Kolovou1, John Boletis1.   

Abstract

OBJECTIVE: The clinical impact of repeat renal biopsies in patients with lupus nephritis (LN) is still debatable. The aim of this retrospective analysis was to assess whether repeat renal biopsy is a reliable tool in guiding therapeutic decisions.
METHODS: Laboratory and histological parameters and therapeutic changes in 35 patients with LN and repeat renal biopsies were retrospectively analyzed. Biopsies were performed in the presence of clinical evidence of an active glomerular disease. Biopsy specimens were retrospectively re-assessed by two renal pathologists and were compared according to the last International Society of Nephrology/ Renal Pathology Society classification.
RESULTS: Thirty-five patients had two, 13 had three, 5 had four, 4 had five, and 1 had six renal biopsies. Fifty-eight comparisons of renal biopsies were made. Median times between the first and second, second and third, third and fourth, and fourth and fifth biopsies were 31, 27, 34, and 28 months, respectively. The mean activity indices from the first to the fifth biopsy were 8.7, 6.6, 7.8, 9.4, and 4.7, whereas the mean chronicity indices were 1.7, 2.3, 4.3, 5.2, and 7.7, respectively. Conversion was observed in 65.5% of cases with the most frequent (21%) being between classes III and IV. Conversion to a more severe type of nephritis occurred in 19% of cases. There was no correlation of laboratory parameters to the type of nephritis upon conversion. In 79% of cases, immunosuppressive therapy was modified after repeat biopsy.
CONCLUSION: Repeat biopsy is a reliable tool for monitoring the activity and chronicity status of LN and for tailoring immunosuppressive therapy to the needs of the patient, especially late in the course of the disease.

Entities:  

Year:  2019        PMID: 31782721      PMCID: PMC7001996          DOI: 10.5152/eurjrheum.2019.18146

Source DB:  PubMed          Journal:  Eur J Rheumatol        ISSN: 2147-9720


  17 in total

1.  Kidney biopsy in lupus nephritis: look before you leap.

Authors:  Geoffrey R Bihl; Michelle Petri; Derek M Fine
Journal:  Nephrol Dial Transplant       Date:  2006-04-21       Impact factor: 5.992

2.  American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis.

Authors:  Bevra H Hahn; Maureen A McMahon; Alan Wilkinson; W Dean Wallace; David I Daikh; John D Fitzgerald; George A Karpouzas; Joan T Merrill; Daniel J Wallace; Jinoos Yazdany; Rosalind Ramsey-Goldman; Karandeep Singh; Mazdak Khalighi; Soo-In Choi; Maneesh Gogia; Suzanne Kafaja; Mohammad Kamgar; Christine Lau; William J Martin; Sefali Parikh; Justin Peng; Anjay Rastogi; Weiling Chen; Jennifer M Grossman
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-06       Impact factor: 4.794

3.  Predictive power of the second renal biopsy in lupus nephritis: significance of macrophages.

Authors:  G S Hill; M Delahousse; D Nochy; P Rémy; F Mignon; J P Méry; J Bariéty
Journal:  Kidney Int       Date:  2001-01       Impact factor: 10.612

4.  Changes in pathological pattern and treatment regimens based on repeat renal biopsy in lupus nephritis.

Authors:  Guo-Bao Wang; Zheng-Jin Xu; Hong-Fa Liu; Qiu-Gen Zhou; Zhan-Mei Zhou; Nan Jia
Journal:  Chin Med J (Engl)       Date:  2012-08       Impact factor: 2.628

Review 5.  Lupus nephritis flares.

Authors:  P I Sidiropoulos; H D Kritikos; D T Boumpas
Journal:  Lupus       Date:  2005       Impact factor: 2.911

6.  Outcomes of children with proliferative lupus nephritis: the role of protocol renal biopsy.

Authors:  David Askenazi; Barry Myones; Ankur Kamdar; Robert Warren; Maria Perez; Marietta De Guzman; Anna Minta; M John Hicks; Arundhati Kale
Journal:  Pediatr Nephrol       Date:  2007-03-03       Impact factor: 3.714

7.  Serial renal biopsy in systemic lupus erythematosus.

Authors:  S Bajaj; L Albert; D D Gladman; M B Urowitz; D C Hallett; S Ritchie
Journal:  J Rheumatol       Date:  2000-12       Impact factor: 4.666

8.  Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a long-term prospective study.

Authors:  John N Boletis; Smaragde Marinaki; Chryssanthe Skalioti; Sofia S Lionaki; Aliki Iniotaki; Petros P Sfikakis
Journal:  Nephrol Dial Transplant       Date:  2009-01-29       Impact factor: 5.992

9.  The clinical relevance of a repeat biopsy in lupus nephritis flares.

Authors:  Gabriëlle M N Daleboudt; Ingeborg M Bajema; Natascha N T Goemaere; Jaap M van Laar; Jan A Bruijn; Stefan P Berger
Journal:  Nephrol Dial Transplant       Date:  2009-07-21       Impact factor: 5.992

10.  Successful treatment of class V+IV lupus nephritis with multitarget therapy.

Authors:  Hao Bao; Zhi-Hong Liu; Hong-Lang Xie; Wei-Xin Hu; Hai-Tao Zhang; Lei-Shi Li
Journal:  J Am Soc Nephrol       Date:  2008-07-02       Impact factor: 10.121

View more
  1 in total

1.  History of proliferative glomerulonephritis predicts end stage kidney disease in pure membranous lupus nephritis.

Authors:  Andrea Fava; Paride Fenaroli; Avi Rosenberg; Serena Bagnasco; Jessica Li; Jose Monroy-Trujillo; Derek Fine; Mohamed G Atta; Michelle Petri
Journal:  Rheumatology (Oxford)       Date:  2022-05-30       Impact factor: 7.046

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.